WallStSmart

ALT5 Sigma Corporation (ALTS)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Zepp Health Corp generates 942% more annual revenue ($258.90M vs $24.84M). ALTS leads profitability with a 0.0% profit margin vs -15.5%. ALTS earns a higher WallStSmart Score of 52/100 (C-).

ALTS

Buy

52

out of 100

Grade: C-

Growth: 7.0Profit: 2.5Value: 5.0Quality: 5.0

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ALTSSignificantly Overvalued (-65.6%)

Margin of Safety

-65.6%

Fair Value

$0.90

Current Price

$0.85

$0.05 premium

UndervaluedFair: $0.90Overvalued
ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALTS3 strengths · Avg: 9.3/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

EPS GrowthGrowth
118.7%10/10

Earnings expanding 118.7% YoY

PEG RatioValuation
0.978/10

Growing faster than its price suggests

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

ALTS4 concerns · Avg: 2.3/10
Market CapQuality
$109.95M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-57.9%2/10

ROE of -57.9% — below average capital efficiency

Operating MarginProfitability
-48.1%1/10

Operating margin of -48.1%

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : ALTS

The strongest argument for ALTS centers on Price/Book, EPS Growth, PEG Ratio. Revenue growth of 12.5% demonstrates continued momentum. PEG of 0.97 suggests the stock is reasonably priced for its growth.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : ALTS

The primary concerns for ALTS are Market Cap, Profit Margin, Return on Equity.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

ALTS profiles as a value stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ALTS carries more volatility with a beta of 2.01 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor SOFTWARE - APPLICATION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ALTS scores higher overall (52/100 vs 41/100) and 12.5% revenue growth. ZEPP offers better value entry with a 48.6% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

ALT5 Sigma Corporation

TECHNOLOGY · SOFTWARE - APPLICATION · USA

ALT5 Sigma Corporation operates a next generation blockchain platform. The company is headquartered in Las Vegas, Nevada.

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?